GAMCO Investors, Inc. reported a 14.9% increase in quarterly revenues to $65.9 million for Q1 2026, alongside a 12.5% rise in assets under management (AUM) to $35.1 billion compared to Q1 2025. The company posted earnings per share (EPS) of $0.66, down from $0.81 the previous year. GAMCO maintains a strong liquidity position with $200.9 million in cash and investments and no debt, supporting capital returns including repurchasing 449,535 shares during the quarter. These results reflect GAMCO's ongoing growth and financial stability in its investment advisory business.
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
Rogers Communications has agreed to buy the remaining 25% stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports for C$4.35 billion, making Rogers the sole owner. This move aims to strengthen Rogers' position in Canadian sports and ente...
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
